SpyGlass Pharma, Inc. logo
SGP

SpyGlass Pharma, Inc.

Last Price US$22.52 Latest stored quote
Market Cap US$752.9m Company size context
7D Performance 17.60% Past 7 days
1Y Performance N/A Past 12 months
Model Rating Not rated Insufficient reported history for the model
Loading Mave Thesis research outlook

Dashboard Funda..tals Prediction Screener Map

SpyGlass Pharma, Inc. Overview

Industry: Medical/Dental Instruments

Sector: Health Care

SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. The SpyGlass Pharma platform, a novel, non-bioerodible drug delivery technology, is designed to be used with various well-established, approved medicines, including bimatoprost and other small molecules, providing flexibility to potentially treat a range of conditions in the front and back of the eye. The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman to solve the lack of ophthalmic innovations that capitalize on durable treatment options. SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's mission is to significantly improve the lives of patients with Read More

Newly listed company coverage

Verified company profile, price history, and SEC registration source are available.

10-Q/10-K financial data, or the foreign-issuer equivalent, is not available yet.

Review the SEC registration filing

Reported Results

No latest earnings report cached yet

Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.

Recent News



Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

Annual 10-K/20-F financial statement data is not available yet.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

SpyGlass Pharma, Inc. logo

SpyGlass Pharma, Inc.

US$22.52

US$752.9m

17.60%

N/A